Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F, Da Silva A, Johnson A, Blanc-Fournier C, Abramovici O, Broyelle A, Levy C, Allouache D, Hrab I, Segura C, Morel A, Villemin M, Boscher C, Dubot-Poitelon C, Rottier P, Lequesne J, Emile G. Cherifi F, et al. Among authors: lequesne j. BMC Cancer. 2022 Oct 20;22(1):1081. doi: 10.1186/s12885-022-10163-9. BMC Cancer. 2022. PMID: 36266623 Free PMC article.
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Lesueur P, Lequesne J, Grellard JM, Dugué A, Coquan E, Brachet PE, Geffrelot J, Kao W, Emery E, Berro DH, Castera L, Goardon N, Lacroix J, Lange M, Capel A, Leconte A, Andre B, Léger A, Lelaidier A, Clarisse B, Stefan D. Lesueur P, et al. Among authors: lequesne j. BMC Cancer. 2019 Mar 4;19(1):198. doi: 10.1186/s12885-019-5413-y. BMC Cancer. 2019. PMID: 30832617 Free PMC article.
Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M, Martel-Lafay I, Lequesne J, Faivre JC, Le Péchoux C, Stefan D, Barraux V, Loiseau C, Grellard JM, Danhier S, Lerouge D, Chouaid C, Gervais R, Thariat J. Kissel M, et al. Among authors: lequesne j. BMC Cancer. 2019 Dec 19;19(1):1237. doi: 10.1186/s12885-019-6449-8. BMC Cancer. 2019. PMID: 31856742 Free PMC article.
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
Clatot F, Perdrix A, Beaussire L, Lequesne J, Lévy C, Emile G, Bubenheim M, Lacaille S, Calbrix C, Augusto L, Guillemet C, Alexandru C, Fontanilles M, Sefrioui D, Burel L, Guénot S, Richard D, Sarafan-Vasseur N, Di Fiore F. Clatot F, et al. Among authors: lequesne j. Breast Cancer Res. 2020 May 28;22(1):56. doi: 10.1186/s13058-020-01290-x. Breast Cancer Res. 2020. PMID: 32466779 Free PMC article.
Post-traumatic stress symptomatology and adjustment of medical oncology practice during the COVID-19 pandemic among adult patients with cancer in a day care hospital.
Joly F, Rigal O, Guittet L, Lefèvre-Arbogast S, Grellard JM, Binarelli G, Lange M, Rieux C, Fernette M, Tron L, Gernier F, Travers R, Morel A, Richard D, Griffon B, Leconte A, Bastien E, Quilan F, Pépin LF, Jardin F, Leheurteur M, Clarisse B, Lequesne J, Faveyrial A. Joly F, et al. Among authors: lequesne j. Cancer. 2021 Dec 15;127(24):4636-4645. doi: 10.1002/cncr.33856. Epub 2021 Aug 16. Cancer. 2021. PMID: 34398970 Free PMC article.
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Joly F, Fabbro M, Follana P, Lequesne J, Medioni J, Lesoin A, Frenel JS, Abadie-Lacourtoisie S, Floquet A, Gladieff L, You B, Gavoille C, Kalbacher E, Briand M, Brachet PE, Giffard F, Weiswald LB, Just PA, Blanc-Fournier C, Leconte A, Clarisse B, Leary A, Poulain L. Joly F, et al. Among authors: lequesne j. Gynecol Oncol. 2022 Apr;165(1):30-39. doi: 10.1016/j.ygyno.2022.01.021. Epub 2022 Feb 2. Gynecol Oncol. 2022. PMID: 35123771 Clinical Trial.
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M, Lequesne J, Leconte A, Corbinais S, Parzy A, Guilloit JM, Varatharajah S, Brachet PE, Dorbeau M, Vaur D, Weiswald LB, Poulain L, Le Gallic C, Castera-Tellier M, Galais MP, Clarisse B. Dos Santos M, et al. Among authors: lequesne j. BMC Cancer. 2022 May 12;22(1):537. doi: 10.1186/s12885-022-09623-z. BMC Cancer. 2022. PMID: 35549674 Free PMC article. Clinical Trial.
73 results